New YorK, NY -- (SBWIRE) -- 01/11/2014 -- To receive alerts before the crowd, please take 7 seconds to sign up for our Premium SMS Alerts. Grab your cell phone and text the word "PICKS" to "555888”.
StockMarketIntel.com issues a special report on the following stocks: Gevo, Inc. (NASDAQ:GEVO), Oramed Pharmaceuticals, Inc. (NASDAQ:ORMP), BIOLASE Inc (NASDAQ:BIOL), Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS).
Gevo, Inc. (NASDAQ:GEVO) ended its recent business day with the tumbled of -3.01% and closed at the price of $1.29 after opening at $1.33. The stock traded during its last trading session with the total volume of 1.37 million shares, as compared to its average volume of 1.86 million shares. Gevo, Inc., a renewable chemicals and biofuels company, focuses on the development and commercialization of alternatives to petroleum-based products based on isobutanol produced from renewable feedstocks.
Has GEVO Found The Bottom And Ready To Gain Momentum? Find Out Here
Oramed Pharmaceuticals, Inc. (NASDAQ:ORMP) remained among the day bullish 18.53% and traded with volume of 1.36 million shares in the last session, as compared to average volume of 696,480.00 shares. In comparison with 52 week range of $4.56 - $29.20, it faced lowest price of $23.00 during the last trading session whereas its day highest price was $29.20. The company’s total market capitalization is $229.77 million, along with 7.95 million shares outstanding. Oramed Pharmaceuticals, Inc., a development stage pharmaceutical company, is engaged in the research and development of pharmaceutical solutions for the use of orally ingestible capsules or pills for delivery of polypeptides.
Will ORMP Continue To Move Higher? Find out via this report
BIOLASE Inc (NASDAQ:BIOL) showed 1.34 million shares in volume during the last trading session, while the average trading volume remained 583,642.00 shares. The stock kicked off its trading session at $2.95 and closed at $3.14 after rallied 9.03%. BIOLASE, Inc., a biomedical company, develops, manufactures, and markets lasers in dentistry and medicine in the Unites States and internationally.
Why Should Investors Buy BIOL After The Recent Gain? Just Go Here and Find Out
Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) stock traded during its last trading session with the total traded volume of 1.34 million shares versus its average volume of 228,077.00 shares. The company opened its trade at the price of $4.58 and its closing price was $4.50 after fell -1.75% for the day. Sunesis Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of oncology therapeutics for the treatment of solid and hematologic cancers.
Has SNSS Found The Bottom and Ready To Move Up? Find Out Here
To receive alerts before the crowd, please take 7 seconds to sign up for our Premium SMS Alerts.
Grab your cell phone and text the word "PICKS" to "555888”.
Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. The disclaimer is to be read and fully understood before using our site, or joining our email list.
Neither StockMarketIntel.com, nor its employees and affiliates are registered as investment advisors or broker/dealers in any jurisdiction whatsoever. Through use of this website viewing or using you agree to hold StockMarketIntel.com, its operators, owners, employees, and affiliates harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. The information contained herein is based on sources that we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. Readers should always do their own due diligence and consult a financial professional. StockMarketIntel.com encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled, or is available from public sources and StockMarketIntel.com makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled company. Any opinions expressed on this website are statements of judgment as of the date of publication and are subject to change without further notice, and may not necessarily be reprinted in future publications or elsewhere.
Read Full disclaimer at: http://stockmarketintel.com/Disclaimer.htm
Copyright © 2005-2014 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)